A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

NCT06917742 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Rheumatoid Arthritis
Systemic Lupus Erythematosus

Interventions

DRUG: CPTX2309
DRUG: CPTX2309

Sponsor

Capstan Therapeutics